Poseida Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Poseida Therapeutics's estimated annual revenue is currently $46.3M per year.
- Poseida Therapeutics received $30.0M in venture funding in April 2018.
- Poseida Therapeutics's estimated revenue per employee is $147,596
- Poseida Therapeutics's total funding is $340.5M.
- Poseida Therapeutics's current valuation is $328.8M. (January 2022)
Employee Data
- Poseida Therapeutics has 314 Employees.
- Poseida Therapeutics grew their employee count by 8% last year.
Poseida Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Poseida Therapeutics?
Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac DNA Modification System, TAL-CLOVER and Cas-CLOVER site-specific nucleases, and Footprint-Free Gene Editing (FFGE). For more information, visit www.poseida.com.
keywords:Automotive,Biotechnology,Healthcare,Pharmaceuticals
$340.5M
Total Funding
314
Number of Employees
$46.3M
Revenue (est)
8%
Employee Growth %
$328.8M
Valuation
N/A
Accelerator
Poseida Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Shipping and Receiving Coordinator | Reveal Email/Phone |
2 | Senior Scientist, Clinical Biomarkers | Reveal Email/Phone |
3 | Senior Process Engineer, MSAT | Reveal Email/Phone |
4 | Director, Financial Planning and Analysis | Reveal Email/Phone |
5 | Associate Director | Reveal Email/Phone |
6 | Sr. Clinical Trial Manager | Reveal Email/Phone |
7 | VP R&D, Gene Therapy | Reveal Email/Phone |
8 | Associate Scientist | Reveal Email/Phone |
9 | VP Immuno-Oncology | Reveal Email/Phone |
10 | Associate Director | Reveal Email/Phone |
Poseida Therapeutics News
Matthew Spear, M.D. is stepping down as chief medical officer of Poseida Therapeutics after almost six years at the company.
Under the terms of the deal, which will involve Takeda utilizing Poseida's piggyBac, Cas-CLOVER, biodegradable DNA and RNA nanoparticle...
Through a collaboration, Takeda Pharmaceutical will apply Poseida Therapeutics' technologies to develop up to eight gene therapies including a...
SAN DIEGO, Aug. 30, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the U.S. Food and ...
SAN DIEGO, June 2, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that its Annual Meeting ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $115.6M | 314 | 13% | $161M |
#2 | $56.9M | 314 | -3% | N/A |
#3 | $38.1M | 314 | 1% | N/A |
#4 | $57.1M | 315 | 10% | N/A |
#5 | $100.6M | 317 | 6% | N/A |
Poseida Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-12-17 | $30.0M | A | Malin Corporation plc | Article |
| 2015-12-29 | $23.0M | Undisclosed | Article | |
| 2018-04-05 | $30.0M | B | Longitude Capital | Article |